Combined FDG and NaF PET/CT study in patients (pts) with metastatic genitourinary tumors (mGU) treated with cabozantinib plus nivolumab plus /- ipilimumab (CaboNivo plus /-Ipi)

被引：0
|
作者：
Lin, Jeffrey
Mortazavi, Amir
Stein, Mark N.
Pal, Sumanta K.
Davarpanah, Nicole N.
Nadal, Rosa Maria
Francis, Deneise C.
Berniger, Marilise Anne
Monk, Paul
Kempf, Jeffrey
Becker, Murray
Sokol, Levi
McKinney, Yolanda
Knopp, Michael V.
Wright, Chadwick
Jung, Alex
Choyke, Peter L.
Mena, Esther
Lindenberg, Liza
Apolo, Andrea B.
机构：
[1] NIH, NCI, Genitourinary Malignancies Branch, Ctr Canc Res, Bethesda, MD USA
[2] Ohio State Univ, Arthur G James Canc Hosp, Wexner Med Ctr, Columbus, OH USA
[3] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA
[4] City Hope Natl Med Ctr, Comprehens Canc Ctr, Duarte, CA USA
[5] NIH, Bethesda, MD USA
[6] NCI, Leidos Biomed Inc, Bethesda, MD USA
[7] Ohio State Univ, Columbus, OH USA
[8] Rutgers Robert Wood Johnson Med Sch, Newark, NJ USA
[9] Mol Imaging Program, Ctr Canc Res, Bethesda, MD USA
[10] Ohio State Univ, Wexner Med Ctr, Columbus, OH USA
[11] City Hope Natl Med Ctr, Duarte, CA USA
[12] NIH, NCI, Bethesda, MD USA
[13] NIH, NCI, Mol Imaging Program, Ctr Canc Res, Bethesda, MD USA
[14] NIH, Washington, DC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.e16017
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16017
引用
收藏
页数：6
相关论文
共 50 条
  • [1] The association of FDG PET/CT and NaF PET/CT with survival outcomes in patients (pts) with metastatic genitourinary malignancies (mGU) treated with cabozantinib plus nivolumab plus /- ipilimumab (CaboNivo plus /- Ipi).
    Simon, Nicholas I.
    Lei, Katherine
    Verdini, Nicholas Peter
    Lin, Jeffrey
    Vega, Andy
    Niglio, Scot Anthony
    Mortazavi, Amir
    Pal, Sumanta K.
    Kempf, Jeffrey
    Becker, Murray
    Knopp, Michael V.
    Wright, Chadwick
    Jung, Alex
    Choyke, Peter L.
    Steinberg, Seth M.
    Mena, Esther
    Lindenberg, Liza
    Apolo, Andrea B.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [2] Circulating tumor cell (CTC) enumeration in patients (pts) with metastatic genitourinary (mGU) tumors treated in a phase I study of cabozantinib and nivolumab (CaboNivo) plus /- ipilimumab (CaboNivolpi).
    Apolo, Andrea B.
    Mortazavi, Amir
    Hu, Zishuo Ian
    Schonhoft, Joseph
    Chu, Lincy
    Anderson, Amanda K. L.
    Wang, Yipeng
    Dittamore, Ryan
    Pal, Sumanta K.
    Lara, Primo
    Stein, Mark N.
    Steinberg, Seth M.
    Mayfield, Christian
    Cordes, Lisa M.
    Mallek, Marissa
    Costello, Rene
    Diaz, Carlos
    Trepel, Jane B.
    Bottaro, Donald P.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] Circulating tumor cell (CTC) enumeration in patients (pts) with metastatic genitourinary (mGU) tumors treated in a phase I study of cabozantinib and nivolumab (CaboNivo) plus /- ipilimumab (CaboNivolpi).
    Hu, Zishuo
    Mortazavi, Amir
    Pal, Sumanta K.
    Lara, Primo
    Mayer, Tina M.
    Steinberg, Seth M.
    Mayfield, Christian
    Graap, Katherine
    Mallek, Marissa
    Costello, Rene
    Diaz, Carlos
    Schonhoft, Joseph
    Wang, Yipeng
    Dittamore, Ryan
    Chu, Lincy
    Trepel, Jane B.
    Bottaro, Donald P.
    Apolo, Andrea B.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [4] Ipilimumab challenge/re-challenge in metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors treated with cabozantinib plus nivolumab (CaboNivo) or cabozantinib plus nivolumab plus ipilimumab (CaboNivoIpi).
    Niglio, Scot Anthony
    Girardi, Daniel Motta
    Mortazavi, Amir
    Lara, Primo
    Pal, Sumanta K.
    Saraiya, Biren
    Cordes, Lisa M.
    Ley, Lisa
    Ortiz, Olena Sierra
    Cadena, Jacqueline
    Diaz, Carlos
    Bagheri, Mohammadhadi H.
    Steinberg, Seth M.
    Costello, Rene
    Streicher, Howard
    Wright, John
    Parnes, Howard L.
    Ning, Yang-Min
    Bottaro, Donald P.
    Apolo, Andrea B.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [5] Prognostic value of sequential 18F-FDG+Na18F PET/CT (NaF plus FDG PET) in metastatic genitourinary (GU) cancer patients (pts) treated with cabozantinib/nivolumab plus /- ipilimumab (CaboNivolpi).
    Verdini, Nicholas Peter
    Lim, Ilhan
    Mena, Esther
    Lindenberg, Liza
    Mortazavi, Amir
    Pal, Sumanta K.
    Lara, Primo
    Graap, Katherine
    Mallek, Marissa
    Keen, Corrine
    Thompson, Ryan
    Mayfield, Christian
    Turrell, Corinne
    Cadena, Jacqueline
    Saraiya, Biren
    Lilly, Ray L.
    Knopp, Michael V.
    Wright, Chadwick
    Steinberg, Seth M.
    Apolo, Andrea B.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [6] A phase I study of cabozantinib plus nivolumab (CaboNivo) and cabonivo plus ipilimumab (CaboNivoIpi) in patients (pts) with refractory metastatic (m) urothelial carcinoma (UC) and other genitourinary (GU) tumors.
    Apolo, Andrea B.
    Mortazavi, Amir
    Stein, Mark N.
    Davarpanah, Nicole N.
    Nadal, Rosa Maria
    Parnes, Howard L.
    Ning, Yangmin M.
    Francis, Deneise C.
    Cordes, Lisa M.
    Berniger, Marilise Anne
    Steinberg, Seth M.
    Agarwal, Piyush K.
    Bagheri, Mohammadhadi H.
    Nanda, Swati
    Monk, Paul
    Lancaster, Tiffany
    Moore, Tina
    Costello, Rene
    Bottaro, Donald P.
    Pal, Sumanta K.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [7] Final results of a phase I study of cabozantinib (cabo) plus nivolumab (nivo) and cabonivo plus ipilimumab (Ipi) in patients (pts) with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies
    Nadal, R.
    Mortazavi, A.
    Stein, M.
    Pal, S. K.
    Davarpanah, N.
    Parnes, H. L.
    Ning, Y. M.
    Cordes, L. M.
    Lin, J.
    Bagheri, M.
    Linderberg, L.
    Berniger, M.
    Steinberg, S. M.
    Moore, T.
    Lancaster, T.
    Aviles, M.
    Costello, R.
    Bottaro, D. P.
    Dahut, W. L.
    Apolo, A. B.
    ANNALS OF ONCOLOGY, 2017, 28
  • [8] Results of phase I plus expansion cohorts of cabozantinib (Cabo) plus nivolumab (Nivo) and CaboNivo plus ipilimumab (Ipi) in patients (pts) with with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies.
    Nadal, Rosa Maria
    Mortazavi, Amir
    Stein, Mark
    Pal, Sumanta K.
    Davarpanah, Nicole N.
    Parnes, Howard L.
    Ning, Yang-Min
    Cordes, Lisa M.
    Bagheri, Mohammadhadi H.
    Lindenberg, Liza
    Thompson, Ryan
    Steinberg, Seth M.
    Moore, Tina
    Lancaster, Tiffany
    Velez, Milisyaris
    Mena, Esther
    Costello, Rene
    Bottaro, Donald
    Dahut, William L.
    Apolo, Andrea B.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [9] A phase I study of cabozantinib plus nivolumab (CaboNivo) and ipilimumab (CaboNivoIpi) in patients (pts) with refractory metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors.
    Apolo, Andrea B.
    Mortazavi, Amir
    Stein, Mark N.
    Pal, Sumanta K.
    Davarpanah, Nicole N.
    Parnes, Howard L.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [10] A phase I study of cabozantinib plus nivolumab (CaboNivo) in patients (pts) refractory metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors
    Apolo, A. B.
    Mortazavi, A.
    Stein, M.
    Pal, S. K.
    Davarpanah, N.
    Parnes, H. L.
    Ning, Y. M.
    Francis, D. C.
    Cordes, L. M.
    Berniger, M.
    Steinberg, S. M.
    Monk, P.
    Lancaster, T.
    Mayer, T.
    Costello, R.
    Bottaro, D. P.
    Dahut, W. L.
    ANNALS OF ONCOLOGY, 2016, 27
12345